Strategic Focus Clinical stage biotech with an immunomodulatory platform targeting inflammatory and autoimmune diseases, plus cancer and liver indications, presenting potential cross-industry collaboration and out-licensing opportunities for partnerships, CDMO support, and co-development.

Dermatology Footprint Recent attendance and poster presentations at the American Academy of Dermatology signal active engagement in inflammatory skin conditions such as psoriasis, creating opening to connect with dermatology-focused pharma, biotechs, and contract research providers for collaboration on oral psoriasis programs.

Leadership & Expertise Key hires in biostatistics, operations, and clinical leadership indicate progression toward formalized drug development and regulatory readiness, offering a chance to engage with the team on strategic advisory, consulting, and potential investment or licensing discussions.

Financial Horizon Early-stage funding and modest revenue figures coupled with a documented $8.7M funding and revenue in the low single digits suggest a ripe window for strategic investment, grant support alliances, or partnership financing to accelerate clinical milestones.

Technology & IP Platform built on Nobel Prize–winning research licensed from Temple University, with a patented approach to native immunotherapy via innate T-Regulatory cell differentiation, presenting opportunities for collaboration with academic centers, licensing discussions, and technology scouting for compatible immuno-oncology and autoimmune disease programs.